HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.
Saved in:
| Title: | HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial. |
|---|---|
| Authors: | Altena R; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Wiklander OPB; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Breast Center, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden., Romdhani NS; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Kistner A; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Klintman M; Division of Oncology, Department of Clinical Sciences, Lund University, and Skåne University Hospital, Lund, Sweden., Skarping I; Division of Oncology, Department of Clinical Sciences, Lund University, and Skåne University Hospital, Lund, Sweden.; Department of Clinical Physiology and Nuclear Medicine, Skane University Hospital, Lund, Sweden., Lindman H; Department of Oncology, Uppsala University hospital, Uppsala, Sweden., Rodriguez VS; Division of Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden., Frisell O; The Swedish Institute for Health Economics, Stockholm, Sweden.; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Solna, Sweden., Lindgren P; The Swedish Institute for Health Economics, Stockholm, Sweden.; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Solna, Sweden., Bratteby K; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Jussing E; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Feldwisch J; Affibody AB, Stockholm, Sweden., Frejd FY; Affibody AB, Stockholm, Sweden.; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Cascales HS; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Siikanen J; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Hindorf C; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden., Tran TA; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Theranostics Trial Center, Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Apr 10; Vol. 16, pp. 1812711. Date of Electronic Publication: 2026 Apr 10 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2026.1812711 |
